Mellitus Health is changing how clinicians manage diabetes through proven clinical tools. Insulin Insights, a decision-support software, helps your healthcare team achieve HbA1c targets through fast and precise analysis of glucometer readings to yield dose-specific recommendations for each patient. Our advanced solutions are based on over 30 years of research, and driven by the passion of Chief Medical Officer Dr. Mayer B. Davidson, former President of the ADA and 2016 ADA Physician Clinician of the Year.

To improve the world of diabetes care, we have assembled a stellar team of medical advisors who are recognized leaders in diabetes care, as well as business advisors with extensive leadership experience.

Board of Directors

David Skibinski, MBA

Chief Executive Officer

Dave Skibinski serves as CEO of Mellitus Health and brings a depth of knowledge and experience in developing and commercializing digital health technologies. His diverse career in healthcare includes over three decades bringing medical products and services to market across multiple technologies.

Most recently, Dave was President & CEO of SnapMD, recognized as the leading enterprise telemedicine platform in the world. Previously, he was President & CEO of QuantumMethod, a strategy and branding agency serving emerging healthcare companies. Dave has been involved in the formation of a dozen healthcare companies in exciting markets such as atrial fibrillation, psoriasis, ambulatory cardiac monitoring, women’s health diagnostics, and more. During a ten-year career with GlaxoSmithKline Dave worked in most major pharmaceutical product categories and engaged nearly every channel of product distribution.

Dave joined Mellitus Health spurred by his passion to improve the delivery of healthcare and help people live healthier and more productive lives. As he often tells the Mellitus team, “while we are certainly a medical software company, our purpose is to help people with diabetes requiring insulin live healthier and empower their providers to confidently move patients to glycemic control.” As a Type II diabetic himself, Dave was motivated by the ground-breaking work of Mellitus co-founder Mayer B. Davidson, MD and his life’s work in the field of diabetes.

Dave holds a Bachelor of Science from Indiana University and an MBA from the University of Southern California and lives in greater Los Angeles.

Steven Yecies

Healthcare investor and entrepreneur Steven Yecies has moved at the forefront of meaningful clinical and process change in healthcare in the U.S. and in major European, Asian and Middle Eastern markets through leadership roles at numerous firms. Most recently, he started and led the venture investments in healthcare IT at OrbiMed Advisors, a premier global investor in healthcare. He previously founded his own investment firm, Chronic Health Capital, which focused on private equity investments in healthcare IT and services, and established the health and wellness business at Scient (NASDAQ: SCNT), where he built more than 40 first generation e-health businesses for national health systems and leading global healthcare enterprises.

Yecies holds an MBA from Harvard Business School; a JD from the University of California, Berkeley; and an AB from Dartmouth College.

“Management of diabetes is a big problem. Mellitus Health’s ability to adjust all insulin prescriptions in ways that significantly lower blood glucose, without incidents of dangerous hypoglycemia, is what drew me to the company. It’s the only firm I’ve seen that provides a universal solution and customizes insulin prescription recommendations for nearly every conceivable insulin combination,” Yecies says.

“The best ideas in healthcare apply globally, with the ability to help patients both inside and outside the U.S., in the office or remotely. Mellitus Health’s software can help any insulin-using patient, anywhere. The telehealth potential is immense, as is its potential for use by physician extenders. It provides a tremendous clinical and administrative value proposition for enterprises, practices and patients.”

Dr. Mayer B. Davidson, recipient of the American Diabetes Association's 2016 Outstanding Physician-Clinician in Diabetes Award

Dr. Mayer B. Davidson

Mayer B. Davidson, MD is Professor of Medicine at both the David Geffen School of Medicine at UCLA and Charles R. Drew University. A renowned researcher and speaker on type 2 diabetes and insulin resistance, he has presented hundreds of lectures nationally and internationally and was the 1997-1998 President of the American Diabetes Association. Dr. Davidson was Founding Editor of Current Diabetes Reports and Editor-in-Chief of Diabetes Care, the leading clinical journal for the diabetes community, from 2002 through 2006. He has served on the Editorial Boards of Diabetes Care, Diabetes Spectrum, Clinical Diabetes, Diabetes Reports, Today in Medicine, Geriatrics, and The Journal of Clinical Endocrinology and Metabolism; he was a Consulting Editor of Hippocrates and an Associate Editor of Endo Trends, and he currently serves on the Editorial Board of Diabetes Research & Clinical Practice. Dr. Davidson’s contributions to medical literature include 168 scientific papers, 31 book chapters, 59 reviews, and 54 editorials and invited articles. His most recent book, Meeting the American Diabetes Association Standards of Care: An Algorithmic Approach to Clinical Care of the Diabetes Patient, was published by the American Diabetes Association in 2010. In 2016 Dr. Davidson received the American Diabetes Association’s Outstanding Physician-Clinician Award.

Josh Davidson

Josh spent the first 13 years of his career in the computer and video game industry, working as a producer, marketer, business development manager, and operations manager for Microsoft, DreamWorks Interactive, Kalisto Entertainment, and Arena.net. Josh has managed multimillion-dollar development teams and helped negotiate and execute investment and sale transactions for technology and technology-related companies.

Eric Edin

Eric Edidin formed Endo Ventures in 2013, soon after his then toddler daughter was diagnosed with type-1 diabetes. Endo was founded in response to a deficit of early-stage capital focused on companies impacting diabetes. Endo is backed by a group of mission oriented investors personally impacted by diabetes. Endo makes investments in game-changing early stage companies improving outcomes in diabetes and other endocrine and autoimmune related disorders. Mr. Edidin is also president of Three B Holdings, a private family investment company, and co-founded Archer Capital Management an institutional asset management firm in 2006. Previously, he was a portfolio manager and co-head of credit investments at York Capital Management, a member of Morgan Stanley Capital Partners global private equity investment team and Blackstone Group’s restructuring advisory team. Mr. Edidin is an executive board member of the JDRF of Los Angeles, and member of the investment committee of the Jewish Communal Fund of NY and the Jewish Federation of Los Angeles. Eric holds a B.B.A. degree with highest distinction from the University of Michigan, and an M.B.A from Harvard Business School. Eric resides in Los Angeles with his wife Yvette and three children.
Michael Margolis1

Michael Margolese

Michael has 15 years of experience as an electrical engineer in the defense and commercial electronics industries. While working at Xilinx, Inc. he received 4 patents and led the development of a wide-band software-defined radio platform. Michael was a Project Lead and Senior Hardware Engineer at L-3 Communications Power Paragon division in Anaheim, California. Michael moved on to DCX-CHOL as a senior hardware engineer, where he helped develop the next generation of hand-held military aircraft payload test sets. Prior to founding Mellitus Health, Michael helped develop complex trading algorithms and now applies these skills in developing the company's core products.

Leadership Team

Dr. Mayer B. Davidson, recipient of the American Diabetes Association's 2016 Outstanding Physician-Clinician in Diabetes Award

Dr. Mayer B. Davidson

Chief Medical Officer

Mayer B. Davidson, MD is Professor of Medicine at both the David Geffen School of Medicine at UCLA and Charles R. Drew University. A renowned researcher and speaker on type 2 diabetes and insulin resistance, he has presented hundreds of lectures nationally and internationally and was the 1997-1998 President of the American Diabetes Association. Dr. Davidson was Founding Editor of Current Diabetes Reports and Editor-in-Chief of Diabetes Care, the leading clinical journal for the diabetes community, from 2002 through 2006. He has served on the Editorial Boards of Diabetes Care, Diabetes Spectrum, Clinical Diabetes, Diabetes Reports, Today in Medicine, Geriatrics, and The Journal of Clinical Endocrinology and Metabolism; he was a Consulting Editor of Hippocrates and an Associate Editor of Endo Trends, and he currently serves on the Editorial Board of Diabetes Research & Clinical Practice. Dr. Davidson’s contributions to medical literature include 168 scientific papers, 31 book chapters, 59 reviews, and 54 editorials and invited articles. His most recent book, Meeting the American Diabetes Association Standards of Care: An Algorithmic Approach to Clinical Care of the Diabetes Patient, was published by the American Diabetes Association in 2010. In 2016 Dr. Davidson received the American Diabetes Association’s Outstanding Physician-Clinician Award.

Dave Skibinski

Chief Executive Officer

Dave Skibinski serves as CEO of Mellitus Health and brings a depth of knowledge and experience in developing and commercializing digital health technologies. His diverse career in healthcare includes over three decades bringing medical products and services to market across multiple technologies.

Most recently, Dave was President & CEO of SnapMD, recognized as the leading enterprise telemedicine platform in the world. Previously, he was President & CEO of QuantumMethod, a strategy and branding agency serving emerging healthcare companies. Dave has been involved in the formation of a dozen healthcare companies in exciting markets such as atrial fibrillation, psoriasis, ambulatory cardiac monitoring, women’s health diagnostics, and more. During a ten-year career with GlaxoSmithKline Dave worked in most major pharmaceutical product categories and engaged nearly every channel of product distribution.

Dave joined Mellitus Health spurred by his passion to improve the delivery of healthcare and help people live healthier and more productive lives. As he often tells the Mellitus team, “while we are certainly a medical software company, our purpose is to help people with diabetes requiring insulin live healthier and empower their providers to confidently move patients to glycemic control.” As a Type II diabetic himself, Dave was motivated by the ground-breaking work of Mellitus co-founder Mayer B. Davidson, MD and his life’s work in the field of diabetes. Dave holds a Bachelor of Science from Indiana University and an MBA from the University of Southern California and lives in greater Los Angeles.

Josh Davidson

Chief Product Officer

Josh spent the first 13 years of his career in the computer and video game industry, working as a producer, marketer, business development manager, and operations manager for Microsoft, DreamWorks Interactive, Kalisto Entertainment, and Arena.net. Josh has managed multimillion-dollar development teams and helped negotiate and execute investment and sale transactions for technology and technology-related companies.
Michael Margolis1

Michael Margolese

Chief Technology Officer

Michael has 15 years of experience as an electrical engineer in the defense and commercial electronics industries. While working at Xilinx, Inc. he received 4 patents and led the development of a wide-band software-defined radio platform. Michael was a Project Lead and Senior Hardware Engineer at L-3 Communications Power Paragon division in Anaheim, California. Michael moved on to DCX-CHOL as a senior hardware engineer, where he helped develop the next generation of hand-held military aircraft payload test sets. Prior to founding Mellitus Health, Michael helped develop complex trading algorithms and now applies these skills in developing the company's core products.

Craig Lewis

Chief Operating Officer

Craig is a 20-year veteran of the financial services industry, including his tenure as Senior Executive Vice President of MBNA America Bank where he helped launch the affinity credit card industry. Craig left MBNA to pursue entrepreneurial ventures in Southern California and has launched and built several companies. Craig joined Mellitus to spearhead fundraising, business development and marketing.

Tim Duggins

Chief Regulatory and Quality Officer

Tim Duggins is a regulatory compliance and quality management system expert who helped develop the ISO, IEC and CSA standards and test methods used in the medical device, pharmaceutical and biologicals industries. These documents, together with quality management systems, establish the foundation of designing and building safe and effective medical products.

Scientific Advisory Board

Dr. John B. Buse

Medical Advisor

John B. Buse, M.D., Ph.D. is the Verne S. Caviness Distinguished Professor of Medicine, Director of the Diabetes Care Center, Chief of the Division of Endocrinology and Executive Associate Dean of Clinical research at UNC, where he is the principal investigator on numerous studies in the prevention and treatment of type 1 and type 2 diabetes mellitus. Dr. Buse served as President of Medicine and Science for the American Diabetes Association in 2008, and in 2011 he was appointed as Chair of the National Diabetes Education Program. Dr. Buse has authored more than 200 publications and received numerous awards and honors.

Dr. Stanley Hsia

Medical Advisor

Dr. Stanley Hsia is an Associate Professor of Medicine at Charles R. Drew University of Medicine and Science, and a Health Sciences Associate Clinical Professor at the David Geffen School of Medicine at UCLA, Los Angeles, CA. He completed his medical school at the University of Toronto, Canada, Internal Medicine residency at Queen's University, Endocrinology Fellowship at the University of Toronto, and did postdoctoral research at the University of California, San Diego. He is certified in Endocrinology & Metabolism by both the American Board of Internal Medicine and the Royal College of Physicians and Surgeons of Canada, and is a Fellow of the American College of Endocrinology as well as a Diplomate of the American Board of Clinical Lipidology. He currently teaches in the Charles R. Drew University-UCLA medicine program, serves as a Clinical Trials Principal Investigator with the National Research Institute (NRI) in Los Angeles and Santa Ana, CA, and practices as a clinical endocrinologist with the Southern California Endocrine Group in Orange, CA. His academic interests focus on insulin resistance and its related conditions, including obesity, diabetes, and dyslipidemia. He has received research grants from the NIH and the American Diabetes Association, and has published numerous original research studies, review articles, CME programs, and book chapters, as well as presenting his research at numerous national and international meetings.
Dr. Vivian Fonseca, medical advisor to Mellitus Health

Dr. Vivian A. Fonseca

Medical Advisor

Vivian A. Fonseca, M.D., F.R.C.P. is Professor of Medicine and Alumni Chair in Diabetes in the Section of Endocrinology, at Tulane University’s Health Sciences Center. He is the principal investigator of the DRMS (diabetes remote management system) study, which is designed to evaluate the effectiveness and possibilities of using a remote technology system to enhance and manage daily care for patients with type 2 diabetes. Dr. Fonseca has conducted trials for most diabetes drugs on the market. A former President of Medicine and Science for the American Diabetes Association, he is editor-in-chief of the Journal of Diabetes Complications and has served as editor-in-chief of Diabetes Care and the Journal of the Metabolic Syndrome and Related Disorders.

Dr. Richard A. Kahn

Medical Advisor

Richard A. Kahn, Ph.D. is an independent consultant/researcher and clinical professor of medicine at the University of North Carolina School of Medicine. A senior staff member of the American Diabetes Association from 1985 until his retirement from the Association in 2009, Dr. Kahn was the Chief Scientific and Medical Officer and was responsible for all the scientific and medical affairs of the Association. Dr. Kahn established the first tissue bank in the Red Cross System and directed a large research laboratory concerned with the pathophysiology of blood cells and the prevention of transfusion-transmitted diseases.

Corporate Advisors

Gary Hutchinson, corporate advisor to Mellitus Health

Gary Hutchinson

Senior Corporate Advisor

Gary Hutchinson is an entrepreneurial executive with more than 25 years in healthcare technology. He is the CEO of ThelioPulse, a spinoff company from the Alfred E. Mann Institute at the University of Southern California (AMI USC), where he is Entrepreneur in Residence. He is also an Adjunct Lecturer at the UCLA Anderson School of Management/Global Access Program. Mr. Hutchinson served as President and CEO of Precision Dynamics Corporation from 2002 to 2010, and under his leadership the company grew from $43 million to $112 million in sales and $2 million to $16 million in EBITDA. Before Precision Dynamics Corporation, he was a founder of Zymed Medical Systems (now Phillips Medical Systems), which became the leader in ambulatory monitoring and arrhythmia algorithms and grew to $25 million in sales and $5 million in EBITDA. After its acquisition in 2000, he served as VP of Phillips’ $200 million Cardiology Products unit. Mr. Hutchinson has experience on the advisory boards of a number of companies, including ORFID, an early-stage company in organic semiconductors and polymer-based radio frequency identification devices at UCLA. He has served on the board of directors for AdvaMed, a healthcare industry advocacy organization; Quinton Instruments, a leader in stress testing; and Cardiac Rehab and Cardiac Imaging Systems. As an investor with HP, WR Hambrecht & Zymed, he led a buyout of Quinton from American Home Products.

Scott Fuller

Corporate Advisor

Scott Fuller, FACHE is Senior Vice President of Joint Ventures and Alliances at Seton Healthcare Family. He joined Seton in 2006 as Vice President and Chief Operating Officer for Seton Highland Lakes Hospital and its health centers. During his tenure with Seton, he went on to run both Seton Highland Lakes and Seton Northwest Hospitals. After serving as Assistant Executive Director of Financial Planning for Scott & White Health, he also served as Director of Strategic and Financial Planning for Phoenix Children’s Hospital. His financial background spans investment banking with Shattuck Hammond Partners, Inc., including mergers, acquisitions and divestitures, financial advisory and tax-exempt debt underwriting, commercial real estate and strategic capital planning. Fuller is a graduate of the Ascension Health Executive Formation Program, class of 2010. He earned his Bachelor of Science from Brigham Young University in 1992 and his Master of Health Services Administration in 1994 from Arizona State University, W.P. Carey School of Business.

Advisors